MedTrace Logo

Aromatase Inhibitor Clinical Trial

NCT00228956 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2008-09-25

No results posted yet for this study

Summary

You are invited to participate in a research study looking at metabolism (breakdown) and effects of aromatase inhibitors. The purpose of this research is to try to identify which women who take an aromatase inhibitor are more likely to have certain benefits or side effects from the drug. We will do so by determining whether there are differences that normally occur in genes that you have inherited from your parents that might influence the way individuals respond to medications. If you agree to participate in this study, you will be asked to sign this informed consent form.

Conditions

Interventions

DRUG

pharmacodynamic analysis

Exemestane 25mg po daily or Letrozole 2.5mg po daily

Sponsors & Collaborators

  • Indiana University School of Medicine

    collaborator OTHER

  • Office of Research on Women's Health (ORWH)

    collaborator NIH

  • National Institute of Environmental Health Sciences (NIEHS)

    collaborator NIH

  • National Institute of General Medical Sciences (NIGMS)

    lead NIH

Principal Investigators

  • Anna Maria Storniolo, MD · Indiana University School of Medicine

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00228956 on ClinicalTrials.gov